In vivo response to growth hormone-releasing peptide-6 in adrenocorticotropin-dependent Cushing’s syndrome by lung carcinoid tumor is associated with growth hormone secretagogue receptor type 1a mRNA expression

2007 ◽  
Vol 30 (4) ◽  
pp. 334-340 ◽  
Author(s):  
M. C. Machado ◽  
S. V. Sá ◽  
T. S. Goldbaum ◽  
M. Catania ◽  
V. C. Campos ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Mrna Expression ◽  
Carcinoid Tumor ◽  
Cushing’S Syndrome ◽  
Cushing's Syndrome ◽  
Receptor Type ◽  
Growth Hormone Secretagogue Receptor ◽  
Growth Hormone Secretagogue ◽  
Lung Carcinoid

scholarly journals Association between tumoral GH-releasing peptide receptor type 1a mRNA expression and in vivo response to GH-releasing peptide-6 in ACTH-dependent Cushing's syndrome patients

2008 ◽  
Vol 158 (5) ◽  
pp. 605-613 ◽  
Author(s):  
Marcio Carlos Machado ◽  
Sandra Valeria de Sa ◽  
Maria Lucia Correa-Giannella ◽  
Ricardo Rodrigues Giorgi ◽  
Maria Adelaide Albergaria Pereira ◽  
...  
Keyword(s):  
Mrna Expression ◽  
Cushing’S Syndrome ◽  
Receptor Gene ◽  
Rna Extraction ◽  
Cushing's Syndrome ◽  
Receptor Type ◽  
Ectopic Acth Syndrome ◽  
Ectopic Acth ◽  
Peptide Receptor

ObjectiveGH secretagogues (GHS) produce exaggerated ACTH and cortisol responses in Cushing's disease (CD) patients, attributable to their direct action on GH-releasing peptide receptor type 1a (GHSR-1a). However, there are no studies correlating the in vivo response to GHS and GHSR-1a mRNA expression in ACTH-dependent Cushing's syndrome (CS) patients. The aim of this study is to correlate the patterns of ACTH and cortisol response to GH-releasing peptide-6 (GHRP-6) to GHSR-1a expression in ACTH-dependent CS patients.DesignProspective study in a tertiary referral hospital center. Fifteen CD patients and two ectopic ACTH syndrome (EAS) patients were studied.MethodsTumor fragments were submitted to RNA extraction, and GHSR-1a expression was studied through real-time qPCR and compared with normal tissue samples. The patients were also submitted to desmopressin test and vasopressin receptor type 1B (AVPR1B) mRNA analysis by qPCR.ResultsGHSR-1a expression was similar in normal pituitary samples and in corticotrophic tumor samples. GHSR-1a expression was higher in patients (CD and EAS) presenting in vivo response to GHRP-6. Higher expression of AVPR1B was observed in the EAS patients responsive to desmopressin, as well as in corticotrophic tumors, as compared with normal pituitary samples, but no correlation between AVPR1B expression and response to desmopressin was observed in the CD patients.ConclusionsOur results revealed a higher expression of GHSR-1a in the ACTH-dependent CS patients responsive to GHRP-6, suggesting an association between receptor gene expression and in vivo response to the secretagogue in both the CD and the EAS patients.

Hexarelin Modulates the Expression of Growth Hormone Secretagogue Receptor Type 1a mRNA at Hypothalamic and Pituitary Sites

2004 ◽  
Vol 80 (1) ◽  
pp. 52-59 ◽  
Author(s):  
Elena Bresciani ◽  
Ralf Nass ◽  
Antonio Torsello ◽  
Bruce Gaylinn ◽  
Roberta Avallone ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Receptor Type ◽  
Growth Hormone Secretagogue Receptor ◽  
Growth Hormone Secretagogue

scholarly journals A Novel Phenotype of Familial Hyperaldosteronism Type III: Concurrence of Aldosteronism and Cushing’s Syndrome

2016 ◽  
Vol 101 (11) ◽  
pp. 4290-4297 ◽  
Author(s):  
Anli Tong ◽  
Guanghua Liu ◽  
Fen Wang ◽  
Jun Jiang ◽  
Zhaoli Yan ◽  
...  
Keyword(s):  
Mrna Expression ◽  
Cushing’S Syndrome ◽  
Cushing's Syndrome ◽  
Channel Blockers ◽  
Type Iii ◽  
Adrenal Hormone ◽  
Familial Hyperaldosteronism ◽  
Bilateral Adrenal Hyperplasia

Context: To date, all the familial hyperaldosteronism type III (FH-III) patients reported presenting with typical primary aldosteronism (PA), without showing other adrenal hormone abnormalities. Objective: This study characterized a novel phenotype of FH-III and explored the possible pathogenesis. Patients and Methods: A male patient presented with severe hypertension and hypokalemia at the age of 2 years and developed Cushing’s syndrome at 20 years. He was diagnosed with PA and Cushing’s syndrome on the basis of typical biochemical findings. He had massive bilateral adrenal hyperplasia and underwent left adrenalectomy. KCNJ5 was sequenced, and secretion of aldosterone and cortisol were observed both in vivo and in vitro. Results: A heterozygous germline p.Glu145Gln mutation of KCNJ5 was identified. ARMC5, PRKAR1A, PDE8B, PDE11A, and PRKACA genes and β-catenin, P53 immunoactivity were normal in the adrenal. CYP11B2 was highly expressed, whereas mRNA expression of CYP11B1, CYP17A1, and STAR was relatively low in the hyperplastic adrenal, compared with normal adrenal cortex and other adrenal diseases. In the primary cell culture of the resected hyperplastic adrenal, verapamil and nifedipine, two calcium channel blockers, markedly inhibited the secretion of both aldosterone and cortisol and the mRNA expression of CYP11B1, CYP11B2, CYP17A1, and STAR. Conclusions: We presented the first FH-III patient who had both severe PA and Cushing’s syndrome. Hypersecretion of cortisol might be ascribed to overly large size of the hyperplastic adrenal because CYP11B1 expression was relatively low in his adrenal. Like aldosterone, synthesis and secretion of cortisol in the mutant adrenal may be mediated by voltage-gated Ca2+ channels.

Homogeneous time-resolved fluorescence-based assay to screen for ligands targeting the growth hormone secretagogue receptor type 1a

2011 ◽  
Vol 408 (2) ◽  
pp. 253-262 ◽  
Author(s):  
Jean-Philippe Leyris ◽  
Thomas Roux ◽  
Eric Trinquet ◽  
Pascal Verdié ◽  
Jean-Alain Fehrentz ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Receptor Type ◽  
Time Resolved Fluorescence ◽  
Growth Hormone Secretagogue Receptor ◽  
Growth Hormone Secretagogue ◽  
Time Resolved
Sign in / Sign up

Export Citation Format

Share Document